← Back to patent-cliff list
Montelukast Gel(Aitiya (Shanghai) Pharma)
Tier C — Watch / tradeMontelukast Gel(Aitiya (Shanghai) Pharma)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYSLTR1
Indications (approved)：痔疮, 手术创口, 烧伤, 伤口感染
Regional status
US
-
EU
-
China
Phase II
2023-08-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Montelukast Gel(Aitiya (Shanghai) Pharma)?
Approved indications include: 痔疮, 手术创口, 烧伤, 伤口感染.
When does the Montelukast Gel(Aitiya (Shanghai) Pharma) patent expire?
No public expiry year is available for Montelukast Gel(Aitiya (Shanghai) Pharma) yet; this page updates once verified.
How do I get a quote for Montelukast Gel(Aitiya (Shanghai) Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02